🇺🇸 FDA
Patent

US 7541040

Chimeric molecule for the treatment of th2-like cytokine mediated disorders

granted A61KA61K47/642A61K47/646

Quick answer

US patent 7541040 (Chimeric molecule for the treatment of th2-like cytokine mediated disorders) held by The United States of America as represented by the Department of Health and Human Serivces expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Department of Health and Human Serivces
Grant date
Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K47/642, A61K47/646, A61K47/6829, A61K47/6849